1988 Volume 16 Issue 1 Pages 5-8
We examined the effects of CS-514, a newly introduced inhibitor of cholesterol biosynthesis, on lipoprotein metabolism of Type III and Type III-like hyperlipoproteinemia (HLP). Two subjects were studied. Case 1 showed typical lipoprotein abnormalities of Type III HLP with apoprotein (apo) E-III deficiency and Case 2 demonstrated broad-β band on paper electrophoresis and increased concentration of intermediate density lipoprotein without apo E abnormality. LDL-cholesterol level was low in both cases. After 3 months of CS-514 treatment, they showed decreased cholesterol and triglyceride concentration in plasma. This was accompanied by a reduction in the lipid content of Sf 20-400 range. On the other hand, LDL-cholesterol rose in both cases.
Since it is unlikely that inhibition of cholesterol biosynthesis causes suppression of LDL-receptor activity, the rise in LDL-cholesterol after the treatment may indicate the accelerated conversion of VLDL-remnant to LDL. Thus, it is speculated that CS-514 can enhance the VLDL-LDL cascade by producing lipoprotein particles which are subject to degradation by lipoprotein lipase.
